Hong Kong will list its second spot Solana ETF, named Pando Solana ETF, on the Hong Kong Stock Exchange on October 13 under the ticker 2831.HK. This addition expands the availability of regulated investment products for Solana (SOL) in Asia, reflecting growing investor interest. Currently, global spot Solana ETFs hold $1.9 billion in net assets with $1.61 billion in cumulative net inflows, showing significant capital flow into these funds. The new listing provides investors in the region with more opportunities to gain direct exposure to Solana through a regulated exchange-traded product.
The news about Hong Kong's second spot Solana ETF listing provides context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Oct 12, 2026 10:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 42 rose and 6 fell today. Among notable movers, XTZ (Tezos) rose 8.86% to Rp5.765 with 100% buy orders, EOS (EOS.IO) gained 8.13% to Rp12.649, and ALGO (Algorand) increased 7.89% to Rp2.271 with a buy order majority of 58%.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
JELD-WEN Holding, Inc. reported a net loss of $17.2 million in Q3 2026, a significant improvement from a $367.6 million loss a year earlier, driven by tariff refunds, productivity gains, and cost reductions. Net revenues slightly declined by 1.4% to ...
Ethereum has achieved end-to-end formal verification of leanVM, a minimal zero-knowledge virtual machine designed to aggregate post-quantum signatures efficiently. This milestone is part of Ethereum's plan to transition its network to quantum-resista...
Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced its participation in several major healthcare conferences from November to December 2026. The company will engage in fireside chat...
